Strategic Partnerships PreventionGenetics recently joined forces with Exact Sciences in 2022, signaling openness to collaboration with industry leaders. This suggests potential for co-development opportunities, expanded test menus, and bundled offerings with cancer diagnostics or related labs.
Clinical Expansion Active growth through expanding test offerings such as PGnome and PGxome, plus ongoing updates to technologies. This indicates a receptive environment for new genetic tests or add-on panels, enabling cross-sell to clinicians and researchers seeking comprehensive genomic solutions.
Key Partnerships Recent collaborations with organizations like Foundation Fighting Blindness and Security Health highlight a pattern of alliance-building with nonprofits and health plans. There is potential to pursue outcomes-based agreements, GUIs or patient-facing programs, and joint studies that demonstrate value.
Market Position With a mid-size profile and revenue in the tens of millions, PreventionGenetics sits between boutique and large-cap players. This positioning can be leveraged to offer flexible, rapid-turnaround, cost-conscious testing to mid-market clinics, hospitals, and specialty practices seeking personalized genetic insights.
글로벌 Capabilities Accreditations (CLIA, ISO 15189) and a global patient/researcher base imply reliability and scalability. Sales opportunities include enterprise deals with international clinics, contract research organizations, and education programs that require compliant, high-quality genetic testing at scale.